Mochida PharmaceuticalMochida Pharmaceutical Co.,Ltd.4534東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥9 is left as operating profit. Revenue changed +11.2% from the prior year, operating profit +24.9%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 9.6% | 0.68× | 6.5% | 1.35× | 8.7% |
| 2023 | 6.4% | 0.64× | 4.1% | 1.33× | 5.5% |
| 2024 | 4.4% | 0.65× | 2.9% | 1.32× | 3.8% |
| 2025 | 5.4% | 0.66× | 3.6% | 1.32× | 4.7% |
| 2026 | 6.8% | 0.68× | 4.6% | 1.38× | 6.3% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 110,179 | 103,261 | 102,885 | 105,159 | 116,951 |
| Cost of revenue | 50,626 | 48,146 | 50,815 | 51,371 | 60,690 |
| Gross profit | 59,553 | 55,114 | 52,070 | 53,787 | 56,260 |
| SG&A | 45,161 | 46,607 | 46,267 | 45,661 | 46,113 |
| Operating income | 14,392 | 8,507 | 5,802 | 8,126 | 10,147 |
| Pretax income | 14,591 | 9,044 | 6,160 | 8,052 | 11,171 |
| Income tax | 4,022 | 2,395 | 1,613 | 2,367 | 3,267 |
| Net income attributable to owners | 10,569 | 6,649 | 4,547 | 5,685 | 7,903 |
| Operating margin | 13.1% | 8.2% | 5.6% | 7.7% | 8.7% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥40.5B | ¥38B | ¥24.3B | ¥48.2B | ¥31.1B |
| Total assets | ¥163.1B | ¥158.8B | ¥158.8B | ¥160.1B | ¥182.7B |
| Net assets | ¥128.6B | ¥126.8B | ¥128B | ¥130.7B | ¥140.3B |
| Share capital | ¥7.23B | ¥7.23B | ¥7.23B | ¥7.23B | ¥7.23B |
| Property, plant and equipment | ¥14.5B | ¥15B | ¥15.9B | ¥15.9B | ¥16.3B |
| Intangible assets excluding goodwill | ¥713M | ¥797M | ¥721M | ¥920M | ¥1.12B |
| Investment securities | ¥16.5B | ¥14.2B | ¥16.1B | ¥15B | ¥39.2B |
| Current assets | ¥121.4B | ¥117.4B | ¥116.7B | ¥119.7B | ¥119B |
| Current liabilities | ¥29.9B | ¥27.3B | ¥26.1B | ¥24.9B | ¥27.7B |
| Trade payables | ¥10.7B | ¥9.05B | ¥11B | ¥7.42B | ¥9.78B |
| Long-term borrowings | — | — | — | — | ¥10B |
| Total liabilities | ¥34.5B | ¥32.1B | ¥30.8B | ¥29.4B | ¥42.4B |
| Equity attributable to owners of parent | ¥121.2B | ¥120.9B | ¥119.1B | ¥121.9B | ¥127.1B |
| Retained earnings | ¥121.7B | ¥118.9B | ¥117B | ¥116.1B | ¥121.3B |
| Treasury stock | -¥9.62B | -¥7.11B | -¥7.02B | -¥3.27B | -¥3.27B |
EDINET (FSA Japan)
有価証券報告書－第88期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第87期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第86期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第85期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第84期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第83期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 50 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.